Ferring Pharmaceuticals products

CHORAGON (u-hCG) is a glycopeptide hormone administered by intramuscular injection and used to control the timing of ovulation.

GONAPEPTYL / DECAPEPTYL* (triptorelin acetat) is a solution for injection containing 0.1 mg/1 ml of triptorelin acetate (per prefilled syringe). It is indicated for the down regulation of the pituitary before and during controlled ovarian hyperstimulation in assisted reproduction techniques.

LUTINUS / ENDOMETRIN (progesterone) is a vaginal tablet containing 100 mg progesterone per tablet. It is indicated for luteal support as part of an Assisted Reproductive Technology (ART) treatment programme for infertile women.

LUTREPULSE® / LUTRELEF® (gonadorelin acetate) is used in replacement therapy of endogenous GnRH-deficiency, for the treatment of infertility in women and men. This can induce sexual development, follicle maturation and ovulation in women whose normal secretion of GnRH (and therefore of FSH and LH) is affected. It can also be used in men to induce sperm production.

CORTIMENT®MMX® (budesonide)* is indicated in adults for induction of remission in patients with active mild-to-moderate active ulcerative colitis where 5-ASA (aminosalicylate) treatment is not sufficient.

GLYPRESSIN (terlipressin) is indicated for the treatment of bleeding oesophageal varices and in some countries for the treatment of hepato-renal syndrome type 1.

PENTASA® (mesalazine) is Ferring’s product used for the treatment and long-term management of inflammatory bowel diseases (IBD) (Ulcerative colitis and Crohn’s disease).

FIRMAGON® (degarelix) is a treatment for men with advanced hormone-dependent prostate cancer. It has a novel mechanism of action that is different from traditional LHRH agonist therapy commonly used. Decreasing testosterone levels can cause the cancer cells to die, thus reducing the size of the tumour and delaying its growth. To date, FIRMAGON has been approved in 74 countries.

MINIRIN® (desmopressin) is indicated for the treatment of bedwetting in children and nocturia in adults. Both conditions are usually caused by an overproduction of urine at night, and MINIRIN acts on the kidneys to reduce this. Bedwetting can be traumatic for children, affecting their well-being and self-esteem. For adults with nocturia, waking up several times a night to urinate can lead to sleep deprivation affecting a patient’s quality of life.

NOCDURNA® (desmopressin) is indicated for the symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults. Nocturia, the need to awaken at night to pass urine, is a complex medical condition with various contributing factors. The night-time overproduction of urine, nocturnal polyuria, is responsible for nocturia in up to 88% of cases. NOCDURNA® once-daily lyophilisate tablets are administered sublingually (without the need for water) in gender specific low doses, tailored specifically for men (50 mcg) and women (25 mcg).